EVM
FOLD

Eaton Vance Management’s Amicus Therapeutics FOLD Stock Holding History

Eaton Vance Management’s Portfolio FOLD Stock Details FOLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-100,110
Closed -$948K – 1664
2022
Q1 		$948K Hold
100,110
– – ﹤0.01% 1376
2021
Q4 		$1.16M Hold
100,110
– – ﹤0.01% 1151
2021
Q3 		$1K Sell
100,110
-122
-0.1% -$1.25K ﹤0.01% 1954
2021
Q2 		$966K Buy
100,232
+100,220
+835,167% +$978K ﹤0.01% 1195
2021
Q1 		$0 Buy
+12
New +$186 ﹤0.01% 2898

Other funds holding FOLD

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Eaton Vance Management's FOLD Position: Q2 2022 in Review

Eaton Vance Management sold out of Amicus Therapeutics (FOLD) in Q2 2022, closing a stake of 100,110 shares — an estimated $948K sold.

Eaton Vance Management first reported a position in FOLD in Q1 2021 and held it in 5 quarters. The position peaked at $1.16M in Q4 2021. 212 funds tracked by Wall St. Rank hold FOLD as of Q2 2022.

  • Eaton Vance Management reported no remaining Amicus Therapeutics position as of Q2 2022 after selling out during the quarter.
  • Eaton Vance Management sold 100,110 Amicus Therapeutics shares in Q2 2022, an estimated $948K.
  • Eaton Vance Management first reported a position in Amicus Therapeutics in Q1 2021 and held it in 5 quarters.
  • Eaton Vance Management's Amicus Therapeutics position peaked at $1.16M in Q4 2021.
  • 212 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q2 2022.

Based on Eaton Vance Management's 13F filing for Q2 2022, filed 15 Aug 2022.